A clinical trial at the National Institutes of Health will evaluate if a dose-sparing strategy to stretch the limited quantities of the monkeypox vaccine is as effective at protecting against the virus as the typical dose.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.